Skip to main content

Year: 2025

Endeavor Bancorp Reports Net Income of $1.1 Million for the Second Quarter of 2025; Highlighted by Continued Loan and Deposit Growth, and NIM Expansion

SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) — Endeavor Bancorp (OTCQX: EDVR) (the “Company” or “Bancorp”), the holding company for Endeavor Bank (the “Bank”), today reported net income of $1.07 million, or $0.25 per diluted share, for the second quarter of 2025, compared to $1.36 million, or $0.32 per diluted share, for the first quarter of 2025, and $760,000, or $0.18 per diluted share, for the second quarter of 2024. All financial results are unaudited. “Our second quarter results reflect the strength of our core banking franchise and the disciplined execution of our strategic growth plan,” said Julie Glance, CFO. “We continued to grow loans and deposits during the quarter while maintaining a strong net interest margin, demonstrating the resilience of our business model in an uncertain interest rate environment. Our strategic investments...

Continue reading

Greene County Bancorp, Inc. Reports Record High Net Income of $31.1 Million for the Fiscal Year Ended June 30, 2025, Announces Plans to Expand into Saratoga County

CATSKILL, N.Y., July 23, 2025 (GLOBE NEWSWIRE) — Greene County Bancorp, Inc. (the “Company”) (NASDAQ: GCBC), the holding company for the Bank of Greene County and its subsidiary Greene County Commercial Bank, today reported net income for the quarter and fiscal year ended June 30, 2025. Net income for the quarter and fiscal year ended June 30, 2025 was $9.3 million, or $0.55 per basic and diluted share, and $31.1 million, or $1.83 per basic and diluted share, respectively, as compared to $6.7 million, or $0.40 per basic and diluted share, and $24.8 million, or $1.45 per basic and diluted share, for the quarter and fiscal year ended June 30, 2024, respectively. Net income increased $2.6 million, or 38.6%, when comparing the quarters ended June 30, 2025 and 2024, and increased $6.3 million, or 25.7%, when comparing the fiscal years...

Continue reading

Philips advances minimally invasive therapy procedures in prostate cancer care with FDA 510(k) clearance for image-guided navigation technology

DynaCAD urology with advanced annotationUroNav cart with advanced annotation optionUroNav with advanced annotationJuly 23, 2025 Supporting prostate cancer diagnosis with more precise guidance for clinicians, offering better patient care Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a major advancement in image-guided navigation for prostate cancer care with the FDA 510(k) clearance of the latest Philips UroNav version. The system includes a new advanced annotation [1] workflow that supports clinicians during focal therapy procedures, helping deliver more precise, minimally invasive care. This release comes at a time of increasing need for innovation in prostate cancer care. Prostate cancer remains the most commonly diagnosed solid tumor...

Continue reading

Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder

Vancouver, Canada, July 23, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the successful completion of site initiation at Tel Aviv Sourasky Medical Center (TASMC) for its Phase I/IIa clinical trial evaluating CMND-100, a proprietary oral drug candidate for Alcohol Use Disorder (AUD). This milestone advances Clearmind’s mission to transform treatment for the global epidemic of AUD, which affects millions and accounts for 2.6 million deaths annually. The Phase I/IIa trial, already underway at prestigious sites, including Yale School of Medicine and Johns Hopkins University in the United...

Continue reading

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body Company advancing pipeline of ADCs using PH1 payload across both Trop2 and an undisclosed target Emerging new preclinical data on impact of PH1 payload against a key oncogenic driver is expected before year-end BOSTON and LONDON, July 23, 2025 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today reiterated its commitment to ongoing research to better understand the multiple effects of its novel spliceosome modulator, PH1, having demonstrated it may also act to inhibit key drivers in cancer tumors. “We are excited to build on the scientific data already established...

Continue reading

Dave to Host Second Quarter 2025 Conference Call on August 6, 2025 at 8:30 a.m. ET

LOS ANGELES, July 23, 2025 (GLOBE NEWSWIRE) — Dave Inc. (“Dave” or the “Company”) (Nasdaq: DAVE), one of the nation’s leading neobanks, will host a conference call on Wednesday, August 6, 2025 at 8:30 a.m. Eastern time to discuss its financial results for the second quarter ended June 30, 2025. The Company’s results will be reported in a press release on the same day, prior to the conference call. Dave management will host the conference call, followed by a question-and-answer period. The conference call details are as follows: Date: Wednesday, August 6, 2025Time: 8:30 a.m. Eastern timeToll-free dial-in number: (866) 652-5200International dial-in number: (412) 317-6060Webcast: link The conference call will also be available for replay in the Events section of the Company’s website, along with the transcript, at https://investors.dave.com. If...

Continue reading

Hudson RPO Acquires Alpha Consulting Group (ACG) Japan

Acquisition Marks Entrance into Japan, Enhancing Hudson RPO’s Already Strong Leadership Position in the APAC Region OLD GREENWICH, Conn., July 23, 2025 (GLOBE NEWSWIRE) — Hudson Global, Inc. (the “Company” or “Hudson RPO”) (Nasdaq: HSON), a leading global total talent solutions company, announced today the acquisition of Alpha Consulting Group (“ACG”), a Japan-based (Tokyo) provider of recruitment services to a variety of companies, ranging from small- and medium-sized businesses to blue-chip and multinational organizations primarily in the IT Services, Technology, and Business Services sectors. Entrance into the Japanese market represents a localization strategy for Hudson RPO in the 2nd largest market within APAC and the 3rd largest market globally. Jake Zabkowicz, Global CEO of Hudson RPO, noted, “Today’s announcement fits well...

Continue reading

IperionX – June 2025 Quarterly Report

CHARLOTTE, N.C., July 23, 2025 (GLOBE NEWSWIRE) — IperionX Limited (IperionX) (NASDAQ: IPX, ASX: IPX) is pleased to present its quarterly report for the period ending June 30, 2025. Key highlights during and subsequent to the end of the quarter include: Commercial operations: production online and commissioning of all major equipment completeSuccessful commissioning of the Titanium Manufacturing Campus in Virginia, with all major scrap-to-forged titanium manufacturing equipment now online and proven to meet operational capacity. Repeated back-to-back production cycles of the Hydrogen Assisted Metallothermic Reduction (HAMRTM) furnace continue to produce high-quality titanium that exceeds industry standards. Commissioning-phase process improvements have reinforced the low-capex modular scalability of the HAMR process and underscore...

Continue reading

Matador Technologies Inc. Secures USD $100 Million Financing Facility to Accelerate Bitcoin Treasury Growth

Key HighlightsStrategic Capitalization: Matador has executed a Purchase Agreement for a USD $100 million secured convertible note facility (the “Facility”) with ATW Partners, featuring an initial USD $10.5 million tranche.Exclusive Use of Proceeds: Proceeds are earmarked for purchasing Bitcoin as part of Matador’s treasury allocation strategy, with the intention of increasing long-term Bitcoin-per-share (BPS).Institutional Partnership: ATW Partners—an institutional investor known for structuring growth-stage financings—brings both capital and strategic depth to Matador’s Bitcoin ecosystem vision. Flexible, Equity-Aligned Structure: The secured convertible notes provide minimally dilutive, price-adaptive funding that converts at market-aligned prices.Accelerates Treasury Plan: Supports Matador’s roadmap to acquire up to 1,000 BTC...

Continue reading

Nuwellis Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

Video webcast now available on-demand MINNEAPOLIS, July 23, 2025 (GLOBE NEWSWIRE) — Nuwellis, Inc., today announced that John Erb, President and Chief Executive Officer of Nuwellis, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference. For the event, Mr. Erb dove deeper into his dedication to the Company, how he got to where he is today, and provided insight into why he is passionate about the Company’s programs in development. The on-demand video webcast is now available on the www.virtualinvestorco.com as well as the Newsroom page under the Investors section of the Company’s website (www.nuwellis.com). About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.